SVB Securities Maintains Outperform on Centessa Pharmaceuticals, Raises Price Target to $11
Portfolio Pulse from Benzinga Newsdesk
SVB Securities analyst David Risinger maintains an Outperform rating on Centessa Pharmaceuticals (NASDAQ:CNTA) and raises the price target from $6 to $11.
August 15, 2023 | 4:55 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
SVB Securities maintains an Outperform rating on Centessa Pharmaceuticals and raises the price target from $6 to $11. This could potentially lead to an increase in the stock's price.
The raised price target by SVB Securities indicates a positive outlook for Centessa Pharmaceuticals. This could potentially attract more investors, leading to an increase in demand for the stock and subsequently, an increase in its price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100